RI
CCCC icon

RTW Investments’s C4 Therapeutics CCCC Stock Holding History

RTW Investments’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,819,472
Closed -$16.6M – 63
2022
Q4 		$16.6M Hold
2,819,472
– – 0.34% 42
2022
Q3 		$24.7M Sell
2,819,472
-275,353
-9% -$2.86M 0.57% 40
2022
Q2 		$23.3M Sell
3,094,825
-1,437,157
-32% -$12.6M 0.6% 39
2022
Q1 		$110M Buy
4,531,982
+2,037,017
+82% +$49.5M 2.28% 14
2021
Q4 		$80.3M Hold
2,494,965
– – 1.17% 29
2021
Q3 		$111M Buy
2,494,965
+345,737
+16% +$14.8M 1.68% 19
2021
Q2 		$81.3M Hold
2,149,228
– – 1.23% 25
2021
Q1 		$79.4M Hold
2,149,228
– – 1.24% 28
2020
Q4 		$68.7M Buy
+2,149,228
New +$62.3M 1.15% 28

Other funds holding CCCC

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments's CCCC Position: Q1 2023 in Review

RTW Investments sold out of C4 Therapeutics (CCCC) in Q1 2023, closing a stake of 2,819,472 shares — an estimated $16.6M sold.

RTW Investments first reported a position in CCCC in Q4 2020 and held it in 9 quarters. The position peaked at $111M in Q3 2021. 120 funds tracked by Wall St. Rank hold CCCC as of Q1 2023.

  • RTW Investments reported no remaining C4 Therapeutics position as of Q1 2023 after selling out during the quarter.
  • RTW Investments sold 2,819,472 C4 Therapeutics shares in Q1 2023, an estimated $16.6M.
  • RTW Investments first reported a position in C4 Therapeutics in Q4 2020 and held it in 9 quarters.
  • RTW Investments's C4 Therapeutics position peaked at $111M in Q3 2021.
  • 120 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2023.

Based on RTW Investments's 13F filing for Q1 2023, filed 15 May 2023.